Altach Biomedical, an early stage company that is working on novel ways to regenerate damaged or diseased musculoskeletal tissues has raised €1.2m to bring its product closer to the market.
This technology reduces the need for invasive surgeries, lowering healthcare costs and improving outcomes for patients.
A Philip Lee team led by Hugo Grattirola and Deirdre Brannigan was pleased to advise Altach Biomedical on this project which involves a more effective alternative to traditional cartilage repair methods. Anna Hickey and Daniel Ryan advised existing shareholder NLC Health Ventures.